1	Supplemental Material		
2 3	SARS-CoV-2 mRNA vaccination fails to elicit humoral and cellular		
5 4	immune responses in multiple sclerosis patients receiving		
5	fingolimod		
6			
7	Lil Meyer-Arndt ^{1, 2, 3} , Julian Braun ^{1, 4,*} , Florent Fauchere ^{1, 4,*} , Kanika Vanshylla ^{5,*} , Lucie Loyal ^{1,}		
8 9	⁴ , Larissa Henze ^{1, 4} , Beate Kruse ^{1, 4} , Manuela Dingeldey ^{1, 4} , Karsten Jürchott ^{1, 4} , Maike Mangold ¹ , Ardit Maraj ¹ , Andre Braginets ¹ , Chotima Böttcher ⁶ , Andreas Nitsche ⁷ , Kathrin de la		
10	Rosa ⁸ , Christoph Ratswohl ⁸ , Birgit Sawitzki ⁹ , Pavlo Holenya ¹⁰ , Ulf Reimer ¹⁰ , Leif E. Sander ¹¹ ,		
11	Florian Klein ^{5, 12, 13} , Friedemann Paul ^{2, 14, *} , Judith Bellmann-Strobl ^{2, 14,*} , Andreas Thiel ^{1, 4, *§} ,		
12 13	Claudia Giesecke-Thiel ^{16, *, §}		
13 14	¹ Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-		
15	Universität zu Berlin, and Berlin Institute of Health, Regenerative Immunology and Aging, BIH Center for		
16 17	Regenerative Therapies, 13353 Berlin, Germany ² Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-		
17 18	Universität zu Berlin, and Berlin Institute of Health, NeuroCure Clinical Research Center, 10117 Berlin, Germany		
19	³ Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-		
20 21	Universität zu Berlin, and Berlin Institute of Health, Department of Neurology with Experimental Neurology, 10117 Berlin, Germany		
22	⁴ Si-M / "Der Simulierte Mensch" a science framework of Technische Universität Berlin and Charité -		
23	Universitätsmedizin Berlin, 10117 Berlin, Germany		
24 25	⁵ Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany		
26	⁶ Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-		
27	Universität zu Berlin, and Berlin Institute of Health, Department of Neuropsychiatry and Laboratory of Molecular		
28 29	Psychiatry, 10117 Berlin, Germany ⁷ Robert Koch Institute, 13353 Berlin, Germany		
30	⁸ Department of Cancer and Immunology, Max-Delbrück-Center for Molecular Medicine in the Helmholtz		
31	Association (MDC), 13125 Berlin, Germany		
32 33	⁹ Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt- Universität zu Berlin, and Berlin Institute of Health, Institute for Medical Immunology, 13353 Berlin, Germany		
34	¹⁰ JPT Peptide Technologies, 12489 Berlin, Germany		
35 36	¹¹ Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt- Universität zu Berlin, and Berlin Institute of Health, Department of Infectious Diseases and Respiratory Medicine,		
37	13353 Berlin, Germany		
38	¹² German Center for Infection Research, Partner Site Bonn-Cologne, 50931 Cologne, Germany		
39 40	 ¹³ Center for Molecular Medicine Cologne (CMMC), University of Cologne, 50931 Cologne, Germany ¹⁴ Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt- 		
40 41	Universität zu Berlin, and Berlin Institute of Health, Experimental and Clinical Research Center, 13125 Berlin,		
42	Germany		
43 44	 ¹⁵ Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), 13125 Berlin, Germany ¹⁶ Max Planck Institute for Molecular Genetics, 14195 Berlin, Germany 		
45	Max Harlot institute for Molecular Cenetics, 14100 Denini, Cenharry		
46	* equal contribution		
47 10	*Co. Corresponding outborn		
48 49	[§] Co-Corresponding authors: Claudia Giesecke-Thiel. Address: Max Planck Institute for Molecular Genetics, Ihnestraße 63, 14195		
50	Berlin, Germany. Phone: 030-8413-1544. Email address: giesecke@molgen.mpg.de.		
51 52	Andreas Thiel. Address: Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies, 13353 Berlin, Germany. Phone: 030-450-539555. Email address: andreas.thiel@charite.de.		
53	The second		
54 55			
55 56			

57 58

Supplemental Methods

59 Assessment of vaccine reactogenicity and severe adverse events

At follow-up visits, participants were asked to report on occurrence and severity of local and systemic reactions
 and severe adverse events (SAEs) during the first seven days after the respective vaccination. SAEs included
 worsening of MS symptoms. Reactogenicity and SAEs were assessed by a modified US Food and Drug
 Administration toxicity scale rating from mild (does not interfere with daily activities) to moderate (interferes
 with daily activities) and severe (daily activities no longer feasible)³⁹.

65

66 SARS-CoV-2 pseudovirus neutralization assay

67 SARS-CoV-2 pseudoviruses were generated by co-transfection of plasmids encoding HIV Tat, HIV Gag/Pol, HIV 68 Rev, luciferase followed by an IRES and ZsGreen, and the SARS-CoV-2 spike protein (Wu01 spike, 69 EPI ISL 406716) into HEK 293T cells using FuGENE 6 Transfection Reagent (Promega). Virus culture 70 supernatant was harvested at 48 h and 72 h post transfection and stored at -80°C till use. Harvested virus was 71 titrated by infecting 293T expressing ACE2⁴² and after a 48-hour incubation at 37°C and 5% CO2, luciferase 72 activity was determined after addition of luciferin/lysis buffer (10 mM MgCl2, 0.3 mM ATP, 0.5 mM Coenzyme 73 A, 17 mM IGEPAL (all Sigma-Aldrich), and 1 mM D-Luciferin (GoldBio) in Tris-HCL) using the Tristar microplate 74 reader (Berthold). Neutralization assays were performed as described before. Briefly, 3-fold serial dilutions of 75 serum (1:10 starting dilution) were co-incubated with pseudovirus supernatants for 1 h at 37°C, following 76 which 293T-ACE-2 cells were added. After 48 h at 37°C and 5% CO₂, luciferase activity was determined using 77 the luciferin/lysis buffer. Background relative light units (RLUs) of non-infected cells was subtracted and 78 50% inhibitory dilution (ID₅₀) were calculated as the serum dilution resulting in a 50% reduction in RLU 79 compared to the untreated virus control wells. ID_{50} values were calculated by plotting a non-linear fit dose 80 response curve in GraphPad Prism 7.0.

81

82 SARS-CoV-2 spike epitope-specific peptide microarray

83 Peptides were synthesized and immobilized on peptide microarray slides as described previously. In brief, the 84 peptides were synthesized using SPOT synthesis, cleaved from the solid support and chemoselectively 85 immobilized on functionalized glass slides. Each peptide was deposited on the microarray in triplicates. The 86 peptide microarrays were incubated with human sera (applied dilution 1:200) in a 96-well microarray 87 incubation chamber for one hour at 30°C, followed by incubation with 0.1 µg/mL fluorescently labelled anti 88 human IgG detection antibody (Jackson Immunoresearch). Washing steps were performed after each 89 incubation step with 0.1 % Tween-20 in 1x TBS. After the final incubation step the microarrays were washed 90 and dried. Each microarray slide was scanned using a GenePix Scanner 4300 SL50 (Molecular Devices). Signal 91 intensities were evaluated using GenePix Pro 7.0 analysis software (Molecular Devices). For each peptide, the 92 MMC2 value of the three triplicates was calculated. The MMC2 value was equal to the mean value of all three 93 instances on the microarray except when the coefficient of variation (CV) - standard-deviation divided by the 94 mean value - was larger than 0.5. In this case the mean of the two values closest to each other (MC2) was 95 assigned to MMC2. Further data analysis and generation of the heatmaps was performed using the statistical 96 computing and graphics software R (Version 4.1.1, <u>www.r-project.org</u>).

97

98 Ex vivo T cell stimulations

In short, PBMC were stimulated with PepMixTM SARS-CoV-2 spike glycoprotein pool 1 (JPT) covering the Nterminal aa residues 1-643 (abbreviated to "S-I") and with PepMixTM SARS-CoV-2 spike glycoprotein pool 2 covering the C-terminal part (aa residues 633-1273, abbreviated to "S-II") at a final concentration of 1 μ g/ml per peptide, respectively. Stimulation controls were performed with equal concentrations of DMSO in PBS (unstimulated control) and 1 μ g/ml per peptide of CEFX Ultra SuperStim pool (JPT) as positive control. All approaches contained 1 μ g/ml purified anti-CD28 (clone CD28.2; BD Biosciences). Incubation was performed at 37°C, 5% CO₂ for 16 h in the presence of 10 μ g/ml brefeldin A (Sigma-Aldrich) during the last 14h. T cell

106 stimulations were stopped by incubation in 20mM EDTA for 5 min.

107 B cell and T cell flow cytometry

For S-I- and S-II-specific T cell analysis, antibodies were used as described before: CD3-FITC (REA613, Miltenyi), CD4-VioGreen (REA623, Miltenyi), CD8-VioBlue (REA734, Miltenyi), CD38-APC (REA671, Miltenyi), HLA-DR-PerCpVio700 (REA805, Miltenyi). For B cell status analysis: CD8 Vioblue (REA734, Miltenyi), IgD BV510 (IA6-2, Biolegend), CD14 BV570 (M5E2, Biolegend), CD21 BV605 (1048, BD), CD3 FITC (REA613, Miltenyi), SLAMF7 PE (162.1, Biolegend), CD27 PE-Dazzle594 (O323, Biolegend), HLADR Percp-Vio770 (REA780, Miltenyi), CD20 PE-Vio770 (REA780, Miltenyi), CD38 APC (REA572, Miltenyi), CD4 AlexaFluor700 (RPA-T4, Biolegend) and CD19 APC-Vio770 (REA675, Miltenyi). For intracellular staining of stimulated T cells, fixation and permeabilization were performed with eBioscience[™] FoxP3 fixation and PermBuffer (Invitrogen) according to the manufacturer's protocol. Intracellular staining was carried out for 30 min in the dark at room temperature with 4-1BB-PE (REA765, Miltenyi) and CD40L-PeVio770 (REA238, Miltenyi). Peripheral blood B and T cell subsets were quantified using the following staining: 50µl of blood were stained for 20 minutes at room temperature in the presence of 1mg/ml Beriglobin (CSL Behring) and the following antibodies at their determined optimum titration: CD4-VioBlue (REA623, Miltenyi), CD3-VioGreen (REA641, Miltenyi), HLA-A2-FITC (REA517, Miltenyi), CCR7-PE (REA108, Miltenyi), CD8-PerCP (REA734, Miltenyi), CD31-PE-Vio770 (REA730, Miltenyi), CD19-APC (REA675, Miltenyi), CD16-AF700 (REA423, Miltenyi), CD45RA-APC-Vio770 (REA1047, Miltenyi). 500µl of cold Erythrocyte lysis buffer (Buffer EL, Quiagen) were added and incubated 30 minutes on ice. 400µl of cold PBS, BSA, 2mM EDTA were then added.





164 Supplemental Fig. 1: SARS-CoV-2 mRNA vaccination-related reactogenicity. a and c, percentage of patients 165 grouped according to treatment with at least one systemic (a) or local (c) reaction. b and d, percentage of 166 patients grouped according to treatment with at least one severe systemic (b) or local (d) reaction. 86% of all 167 patients reported vaccination-associated side effects during the first seven days following at least one of the 168 two vaccinations: 79% after the primary vaccination, 82% after the secondary dose, without significant 169 differences between treatment groups. No serious adverse events were reported. Transient worsening of pre-170 existing neurological symptoms associated with MS was described by three patients after primary vaccination 171 and nine patients after secondary vaccination, but no treatment group-dependent patterns were observed. 172 Two patients on aCD20-BCD therapies tested positive for SARS-CoV-2 during the study after 1m and 3m, 173 respectively, both with mild symptoms (WHO classification II). They were subsequently excluded from further 174 analyses. 175





Supplemental Fig. 2. Association of anti-S1 IgG levels and neutralizing capacity. Correlation of anti-S1 IgG and
 neutralizing capacity in serum at 3m for untreated MS patients (MS-untreated) (a), MS-aCD20-BCD (b), and MS FTY720 (c), MS-IFNβ (d), MS-DMF (e), MS-GA (f), MS-TFN (g), and MS-NTZ (h). Simple linear regression tests
 performed per treatment; correlation coefficients depicted as lines and reported as r (for Pearson correlation)
 and rho (for Spearman rank correlation), respectively, with corresponding p-values.



Supplemental Fig. 3. Total number and relative frequencies of peripheral blood CD19⁺ B cells. a) Frequencies of CD19⁺ B cells in total lymphocytes and b) total number of CD19⁺ B cells per μ l per treatment group. Kruskal-Wallis test followed by Dunn's multiple comparisons test performed to test between treatment groups at the respective time point were reported for comparison to untreated patients as: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.001.



218

219 Supplemental Fig. 4. Gating strategy of RBD- and S2-specific B cells. a, B cells are gated from peripheral blood 220 mononuclear cells (PBMCs; FSC-A vs SSC-A), by first excluding doublets (FSC-A vs FSC-H and SSC-A vs SSC-H), 221 gating on CD19⁺CD3⁻ B cells, excluding both dead cells (LiveDead Zombie Yellow) and CD14⁺ cells, and finally by 222 excluding CD20⁻ CD27⁻ cells. Among CD19⁺CD3⁻ B cells, plasmablasts were identified as CD20^{-/low}CD27⁺⁺CD38⁺⁺ 223 cells. CD20⁺ B cells were further classified into subpopulations based on their CD27 and IgD expression. 224 CD20⁺CD27⁺IgD⁻ were classified as classical memory B cells (mBC), CD20⁺CD27⁺IgD⁺ were classified as double 225 positive mBC (dp mbC), CD20⁺CD27⁻IgD⁻ were classified as double negative mBC (dn mBC), and CD20⁺CD27⁻IgD⁺ 226 were classified as naïve B cells (nB). b, exemplary contour plots showing gating of S2-specific B cells and RBD-227 specific B cells, and again their subsequent subpopulation classification based on their CD27 and IgD 228 expression.

- 230
- 231
- 232

Supplemental Fig. 5



Supplemental Fig. 5. Gating strategy of antigen-reactive CD4⁺ T cells and differences between DMT treatment
 groups. a, antigen-reactive CD40L⁺4-1BB⁺CD4⁺ T cells were gated by controlling for measurement-dependent
 artefacts (Time vs SSC-a) from antigen-stimulated PBMC (FSC-A vs SSC-A), by first excluding doublets (FSC-H vs
 FSC-W and SSC-H vs SSC-W), dead cells (LiveDead Zombie Yellow), then gating on CD3⁺ T cells and CD4⁺ double
 positive cells. b, exemplary contour plots showing CD40L and 4-1BB expression in unstimulated control, S-I-,
 and S-II-stimulated CD4⁺ T cells, displayed for the seven different DMT treatment groups at around two months
 after secondary SARS-CoV-2 mRNA vaccination.

Filename: Directory:

MSVX_Supplement_31012022.docx

/Users/lilmeyerarndt/Library/Containers/com.microsoft.Word

	103013	/ mine yer ar nut/ Libra	
/Data/Documents			
Template:	Norma	l.dotm	
Title:			
Subject:			
Author:	Meyer	Arndt, Lil Antonia	
Keywords:			
Comments:			
Creation Date:	14/01/	2022 11:38:00	
Change Number:	61		
Last Saved On:	31/01/	2022 18:33:00	
Last Saved By:	Meyer	Arndt, Lil Antonia	
Total Editing Time:	17 Min	utes	
Last Printed On:	31/01/	2022 18:34:00	
As of Last Complete Printing			
Number of Pages: 7			
Number of Words:		1,888	
Number of Characters:		15,661 (approx.)	